It is different from BCEM because there is a proliferation, or an increase in the number of melanocytes, which is attributed to greater risk of neoplasia formation. However, PAM may occur without atypia, which has no risk of malignant transformation, or with atypia. It is very important to determine at which age the lesion was first noticed because it is more likely to be a benign nevus, or mole, the earlier it is found. It may appear similar to BCEM since the lesion may also be flat, brown or blue-gray, and diffuse throughout the conjunctiva, but it is almost always only found on one eye. Diagnosis
Usually unilateral, flat, patchy, pigmented area that involves the limbus (the border of the cornea and sclera) and interpalpebral (between the eyelids) conjunctiva. Slit-lamp examination. Histopathological examination that shows intraepithelial proliferation of conjunctival epithelial melanocytes. Features that may encourage the ophthalmologist to biopsy the lesion include, but are not limited to:Increasing size or size greater than 5mm
Involvement of conjunctiva underneath the eyelids
Nodular appearance
Appearance of blood vessels surrounding the patch
Previous history of melanoma

Treatment
There are a few management and treatment strategies for PAM. When lesions are small, they can be carefully watched on an annual basis. It is important to compare pictures year to year. However, for medium and large-sized lesions, we can consider surgery (excisional vs incisional biopsy), chemotherapy, or cryotherapy.When a patient has PAM with atypia, an excisional biopsy with cryotherapy is recommended as the treatment. For some patients with diffuse lesions, surgery is not an option.
Light chain deposition disease (LCDD) is a rare blood cell disease which is characterized by deposition of fragments of infection-fighting immunoglobulins,  called light chains (LCs), in the body. LCs are normally cleared by the kidneys, but in LCDD, these light chain deposits damage organs and cause disease. The kidneys are almost always affected and this often leads to kidney failure. About half of people with light chain deposition disease also have a plasma cell dyscrasia, a spectrum of diseases that includes multiple myeloma, Waldenströms macroglobulinemia, and the monoclonal gammopathy of undetermined significance premalignant stages of these two diseases. Unlike in AL amyloidosis, in which light chains are laid down in characteristic amyloid deposits, in LCDD, light chains are deposited in non-amyloid granules. Signs and symptoms
The kidney is the organ most frequently affected. Proteinuria, the presence of protein in the urine, is characteristic. More than 90% of people with LCDD develop kidney failure, often with rapid progression of disease.Light chains may be deposited in many other organs and may or may not result in any symptoms. Other than the kidneys, liver and heart are the most commonly involved organs. Deposition of light chains in the liver may lead to hepatomegaly, an enlarged liver, or rarely portal hypertension or liver failure. The heart is affected in up to 80% of patients with LCDD, and may cause arrhythmias and congestive heart failure. Cause
Diagnosis
A number of laboratory tests are required in order to assist in diagnosing LCDD.